Format

Send to

Choose Destination
Int J Infect Dis. 2008 Sep;12(5):466-71. doi: 10.1016/j.ijid.2008.01.006. Epub 2008 Apr 8.

Is phage therapy acceptable in the immunocompromised host?

Author information

1
Department of Clinical Immunology, Transplantation Institute, The Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland. jborysowski@interia.pl

Abstract

Over the last decade, bacteriophages (bacterial viruses) have emerged as the major alternative to antibiotics in the treatment of antibiotic-resistant infections. While a considerable body of evidence has accumulated for the efficacy and safety of phage therapy in immunocompetent patients, data remain relatively scarce regarding its use in the immunocompromised host. To our knowledge, the present article is the first to summarize all findings, of both experimental and clinical studies, that may be relevant to the employment of phage therapy in immunocompromised patients. The available data suggest that bacteriophages could also be an efficacious and safe therapeutic modality in such patients.

PMID:
18400541
DOI:
10.1016/j.ijid.2008.01.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center